Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 517-527

  Tamma, Pranita D ^a   Hsu, Alice J ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Daptomycin; Enterococcus faecium; Linezolid; Quinupristin dalfopristin; Vancomycin resistant enterococci

Indexed keywords

AMPICILLIN; CREATINE KINASE; DALBAVANCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; ORITAVANCIN; SEROTONIN UPTAKE INHIBITOR; TEDIZOLID; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN; VIRGINIAMYCIN;

ANEMIA; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BACTERIOSTASIS; BRAIN ABSCESS; CHILD; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LACTIC ACIDOSIS; LOEFFLER PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NECROTIZING ENTEROCOLITIS; NONHUMAN; PHLEBITIS; RENAL REPLACEMENT THERAPY; REVIEW; RHABDOMYOLYSIS; SEROTONIN SYNDROME; SIDE EFFECT; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTION; ADOLESCENT; DRUG EFFECTS; GRAM-POSITIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PRESCHOOL CHILD; RISK FACTOR; TREATMENT OUTCOME;

ACETAMIDES; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; RISK FACTORS; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN-RESISTANT ENTEROCOCCI; VIRGINIAMYCIN;

EID: 84927799552     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000115     Document Type: Review

References (188)

1. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobialresistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996-1011.
2. Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008; 6:637-655.
3. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010; 16:555-562.
4. Synercid. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008.050748s008,050747s008lbl.pdf [Accessed 20 August 2014]
5. Synercid [package insert]. Parsipanny, NJ. Aventis Pharmaceutical Products Inc; 2000.
6. Allington DR, Rivey MP. Quinupristin/dalfopristin: a therapeutic review. Clin Ther 2001; 23:24-44.
7. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997; 39 (Suppl A):7-13.
8. Dowzicky M, Nadler HL, Feger C, et al. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med 1998; 104 (5A):34S-42S.
9. Jones RN, Ballow CH, Biedenbach DJ, et al. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998; 31:437-451.
10. Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002; 46:1845-1850.
11. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/ dalfopristin: administration guidelines. J Antimicrob Chemother 1999; 44 (Suppl A):37-46.
12. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001; 32:e83-e86.
13. Bearden DT. Clinical pharmacokinetics of quinupristin/dalfopristin. Clin Pharmacokinet 2004; 43:239-252.
14. Verma A, Dhawan A, Philpott-Howard J, et al. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin. J Antimicrob Chemother 2001; 47:105-108.
15. Gray JW, Darbyshire PJ, Beath SV, et al. Experience with quinupristin/ dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children. Pediatr Infect Dis J 2000; 19:234-238.
16. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44:251-261.
17. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycinresistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001; 33:1816-1823.
18. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/ dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997; 39 (Suppl A):145-151.
19. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44:263-273.
20. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775-784.
21. Raad I, Hachem R, Hanna H, et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001; 45:3202-3204.
22. Winston DJ, Emmanouilides C, Kroeber A, et al. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000; 30:790-797.
23. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004; 53:646-649.
24. Carver PL, Whang E, VandenBussche HL, et al. Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 2003; 23:159-164.
25. Gupte G, Jyothi S, Beath SV, Kelly DA. Quinupristin-dalfopristin use in children is associated with arthralgias and myalgias. Pediatr Infect Dis J 2006; 25:281.
26. McDonald LC, Rossiter S, Mackinson C, et al. Quinupristin-dalfopristinresistant Enterococcus faecium on chicken and in human stool specimens. N Engl J Med 2001; 345:1155-1160.
27. Biedenbach DJ, Ballow C, Schentag JJ, et al. Quinupristin/dalfopristin antimicrobial activity and sepctrum in North America: report from 1998 isolates in the global SMART study [abstract P168]. J Antimicrob Chemother 1999; 44 (Suppl A):77.
28. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristindalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004; 38:92-98.
29. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135-142.
30. Patel U, Yan YP, Hobbs FW Jr, et al. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation. J Biol Chem 2001; 276: 37199-37205.
31. Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 2010; 32:66-88.
32. Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. ExpertOpin Pharmacother 2005; 6:2315-2326.
33. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 (Suppl 2):ii17-ii25.
34. Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycinresistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001; 20:432-434.
35. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46:1475-1480.
36. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:73-77.
37. Kumar S, Kohlhoff S, Valencia G, et al. Treatment of vancomycin-resistant Enterococcus faecium ventriculitis in a neonate. Int J Antimicrob Agents 2007; 29:740-741.
38. Langgartner M, Mutenthaler A, Haiden N, et al. Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants. Arch Dis Child Fetal Neonatal Ed 2008; 93:F397.
39. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002; 21:798-800.
40. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45:1843-1846.
41. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42:1129-1140.
42. Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32:2437-2442.
43. Kearns GL, Jungbluth GL, Abdel-Rahman SM, et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003; 74:413-422.
44. Hoehn R, Groll AH, Schaefer V, et al. Linezolid treatment of glycopeptideresistant Enterococcus faecium in very low birth weight premature neonates. Int J Antimicrob Agents 2006; 27:256-258.
45. Kocher S, Muller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review. Int J Antimicrob Agents 2010; 36:106-110.
46. Pharmacia & Upjohn Company. Zyvox: linezolid injection, linezolid tablets, linezolid for oral suspension package insert. Kalamazoo, MI: Pharmacia & Upjohn Company, 2002.
47. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22 (Suppl 9): S153-S157.
48. Ang JY, Lua JL, Turner DR, Asmar BI. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003; 22:1101-1103.
49. Dresser LD, Birmingham MC, Karchmer AW, et al. Results of treating infective endocarditis with linezolid [abstract 2239]. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 2000.
50. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36:159-168.
51. Steinmetz MP, Vogelbaum MA, De Georgia MA, et al. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 2001; 29:2383-2385.
52. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001; 33:477-482.
53. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008; 46:30-36.
54. Chong YP, Lee SO, Song EH, et al. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance. Scand J Infect Dis 2010; 42:491-499.
55. Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J 2001; 20:488-494.
56. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22:677-686.
57. Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003; 22 (Suppl 9):S158-S163.
58. Meissner HC, Townsend T, Wenman W, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22 (Suppl 9): S186-S192.
59. Jantausch BA, Deville J, Adler S, et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J 2003; 22 (Suppl 9):S164-S171.
60. Wible K, Tregnaghi M, Bruss J, et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22:315-323.
61. Yogev R, Patterson LE, Kaplan SL, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22 (Suppl 9):S172-S177.
62. Maranich AM, Rajnik M. Successful treatment of vancomycin-resistant enterococcal ventriculitis in a pediatric patient with linezolid. Mil Med 2008; 173:927-929.
63. Baysallar M, Izci Y, Kilic A, et al. A case of ventricular drainage infection with a rare pathogen in cerebrospinal fluid: vancomycin-resistant Enterococcus faecium. Microbial Drug Resist 2006; 12:59-62.
64. Dinleyici EC, Yarar C, Dinleyici M, Yakut A. Successful treatment with linezolid of meningitis complicated with subdural empyema in a 6-monthold boy. J Trop Pediatr 2007; 53:431-433.
65. Gallagher RM, Pizer B, Ellison JA, Riordan FA. Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin. J Infect 2008; 57:410-413.
66. Milstone AM, Dick J, Carson B, Siberry GK. Cerebrospinal fluid penetration and bacteriostatic activity of linezolid against Enterococcus faecalis in a child with a ventriculoperitoneal shunt infection. Pediatr Neurosurg 2007; 43:406-409.
67. Godon N, Denizot S, Podevin G, et al. Effectiveness of linezolid and imipenem association in the treatment of severe community-acquired pneumonia in children: two case reports. Scand J Infect Dis 2006; 38:381-383.
68. Travaglianti M, Perez M, Sberna N, et al. [Treatment of vancomycin-resistant Enterococcus with linezolid in paediatric hospitals]. Farm Hosp 2007; 31:43-47.
69. Chen CJ, Chiu CH, Lin TY, et al. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007; 26:985-988.
70. Verma N, Clarke RW, Bolton-Maggs PH, van Saene HK. Gut overgrowth of vancomycin-resistant enterococci (VRE) results in linezolid-resistant mutation in a child with severe congenital neutropenia: a case report. J Pediatr Hematol Oncol 2007; 29:557-560.
71. Deville JG, Goldfarb J, Kaplan SL, et al. The use of linezolid in the treatment of paediatric patients with infections caused by enterococci including strains resistant to vancomycin. J Antimicrob Chemother 2010; 65:2267-2270.
72. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723-2726.
73. El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis 2003; 5:121-125.
74. Forrest A, Rayner CR, Meagher AK, Birmingham MC, Schentag JJ. Pharmacostatistical modelling of hematologic effects of linezolid in serious-ill patients [abstract 283]. In: Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy.
75. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66-72.
76. Jones SJ, Nichols KR, DeYoung HL, et al. Linezolid-associated thrombocytopenia in children with renal impariment. J Pediatr Infect Dis Soc 2014; pp. 1-4, DOI: 10.1093/jpids/piu035.
77. Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010; 36:179-181.
78. Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 2013; 68:2128-2133.
79. Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28:345-351.
80. Hiraki Y, Tsuji Y, Matsumoto K, et al. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci 2011; 342:456-460.
81. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695-698.
82. Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 2004; 54:798-802.
83. Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113-e116.
84. Su E, Crowley K, Carcillo JA, Michaels MG. Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J 2011; 30:804-806.
85. Pea F, Scudeller L, Lugano M, et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006; 42:434-435.
86. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27:1189-1197.
87. Beekmann SE, Gilbert DN, Polgreen PM, Network IEI. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 2008; 62:407-410.
88. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4:528-531.
89. Azamfirei L, Copotoiu SM, Branzaniuc K, et al. Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy. Pharmacoepidemiol Drug Saf 2007; 16:402-404.
90. Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37:1389-1391.
91. Joshi L, Taylor SR, Large O, et al. A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukaemia. Clin Infect Dis 2009; 48:e73-e74.
92. Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006; 66:595-598.
93. Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155-1163.
94. Linam WM, Wesselkamper K, Gerber MA. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 2009; 28:149-151.
95. Brennan K, Jones BL, Jackson L. Auditory nerve neuropathy in a neonate after linezolid treatment. Pediatr Infect Dis J 2009; 28:169.
96. Javaheri M, Khurana RN, O'Hearn TM, et al. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007; 91:111-115.
97. Nambiar S, Rellosa N, Wassel RT, et al. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics 2011; 127:e1528-e1532.
98. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005; 28:205-214.
99. Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004; 25:215-221.
100. Lawrence KR, AdraM, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578-1583.
101. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180-187.
102. Klasko RK, ed. DRUGDEX system. Thomson Micromedex: Greenwood Village, Colorado. 2005.
103. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346: 867-869.
104. Ruggero KA, Schroeder LK, Schreckenberger PC, et al. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003; 47:511-513.
105. Mendes RE, Deshpande LM, Jones RN. Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat 2014; 17:1-12.
106. Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007; 58:163-170.
107. Patel SN, Memari N, Shahinas D, et al. Linezolid resistance in Enterococcus faecium isolated in Ontario, Canada. Diagn Microbiol Infect Dis 2013; 77:350-353.
108. Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000; 46:523-526.
109. Laganas V, Alder J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother 2003; 47:2682-2684.
110. Jacobson LM,Milstone AM, Zenilman J, et al. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2009; 28:445-447.
111. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011; 31:527-536.
112. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.
113. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-665.
114. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillinresistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45:454-459.
115. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007; 60:334-340.
116. Rose WE, Leonard SN, Sakoulas G, et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52:831-836.
117. Chambers HF, Basuino L, Diep BA, et al. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob Agents Chemother 2009; 53:1463-1467.
118. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003; 47:1598-1603.
119. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004; 24:41-57.
120. Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008; 27:330-334.
121. Dvorchik B, Arbeit RD, Chung J, et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004; 48:2799-2807.
122. Cubicin (Daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals, 2010.
123. Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2011; 30:712-714.
124. Bradley JS, Benziger D, Bokesch P, Jacobs RF. Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age. Pediatr Infect Dis J 2014; 33:936-939.
125. Cohen-Wolkowiez M, Watt KM, Hornik CP, et al. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J 2012; 31:935-937.
126. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-292.
127. Eisenstein BI, Oleson FB Jr, Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 2010; 50 (Suppl 1):S10-S15.
128. Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57:1568-1576.
129. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50:1568-1574.
130. Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44:2948-2953.
131. Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, et al. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother 2008; 52:1891-1893.
132. Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, et al. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol 2008; 28:233-234.
133. Sarafidis K, Iosifidis E, Gikas E, et al. Daptomycin use in a neonate: serum level monitoring and outcome. Am J Perinatol 2010; 27:421-424.
134. Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. Infection 2012; 40:367-371.
135. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47:1318-1323.
136. Elvy J, Porter D, Brown E. Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. J Antimicrob Chemother 2008; 61:461-462.
137. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:1058-1060.
138. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55:283-288.
139. Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin-and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928-3933.
140. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149-2152.
141. Whang DW, Miller LG, Partain NM, McKinnell JA. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycinresistant enterococcal bloodstream infections. Antimicrob Agents Chemother 2013; 57:5013-5018.
142. Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014; 58:734-739.
143. Hayakawa K, Martin ET, Gudur UM, et al. Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. Antimicrob Agents Chemother 2014; 58:3968-3975.
144. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008; 62:1455-1464.
145. Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009; 33: 543-548.
146. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177-180.
147. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (> or1/48 mg/kg) daptomycin therapy. Ann Pharmacother 2009; 43:1211-1219.
148. Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother 2013; 57:4190-4196.
149. Ardura MI, Mejias A, Katz KS, et al. Daptomycin therapy for invasive Grampositive bacterial infections in children. Pediatr Infect Dis J 2007; 26:1128-1132.
150. Beneri CA, Nicolau DP, Seiden HS, Rubin LG. Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a daptomycin-containing regimen. Infect Drug Resist 2008; 1:9-11.
151. Palma DM, Giordano S, Neville Cracchiolo A, et al. Daptomycin in the treatment of invasive Gram-positive bacterial infections in children: personal experience. Minerva Pediatr 2013; 65:173-178.
152. Larru B, Cowden CL, Zaoutis TE, Gerber JS. Daptomycin use in United States children's hospitals. J Pediatr Infect Dis Soc 2014; Advanced Access.
153. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology 2008; 81:79-91.
154. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245-3249.
155. Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 2006; 57:578-579.
156. Veligandla SR, Louie KR, Malesker MA, Smith PW. Muscle pain associated with daptomycin. Ann Pharmacother 2004; 38:1860-1862.
157. Echevarria K, Datta P, Cadena J, Lewis JS 2nd. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005; 55:599-600.
158. Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 2010; 50:737-740.
159. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011; 52:228-234.
160. Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010; 65:1126-1136.
161. Kamboj M, Cohen N, Gilhuley K, et al. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 2011; 32:391-394.
162. Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365:892-900.
163. Munita JM, Panesso D, Diaz L, et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 2012; 56:4354-4359.
164. Tran TT, Panesso D, Gao H, et al. Whole-genome analysis of a daptomycinsusceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 2013; 57: 261-268.
165. Tran TT, Panesso D, Mishra NN, et al. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio 2013; 4.
166. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394-e434.
167. Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycinresistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45:1343-1346.
168. Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann Pharmacother 2004; 38:989-991.
169. Safdar A, Bryan CS, Stinson S, Saunders DE. Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: treatment with chloramphenicol plus minocycline. Clin Infect Dis 2002; 34:E61-E63.
170. Jenkins I. Linezolid-and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007; 2:343-344.
171. Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005; 41:1134-1142.
172. Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. South Med J 2003; 96:818-820.
173. Matsumura S, Simor AE. Treatment of endocarditis due to vancomycinresistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 1998; 27:1554-1556.
174. Tripodi MF, Locatelli A, Adinolfi LE, et al. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicinresistant enterococci. Eur J Clin Microbiol Infect Dis 1998; 17:734-736.
175. Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microbial Drug Resist 1995; 1:249-253.
176. Dodge RA, Daly JS, Davaro R, Glew RH. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant enterococci. Clin Infect Dis 1997; 25:1269-1270.
177. Jones BL, Ludlam HA, Brown DF. High dose ampicillin for the treatment of high-level aminoglycoside resistant enterococcal endocarditis. J Antimicrob Chemother 1994; 33:891-892.
178. Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycinand cationic host defense peptide-mediated killing of ampicillin-and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56:838-844.
179. Arhin FF, Sarmiento I, Belley A, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 2008; 52:1597-1603.
180. McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009; 63:1191-1199.
181. Streit JM, Sader HS, Fritsche TR, Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005; 53:307-310.
182. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005; 11:95-100.
183. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. In-vitro and invivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999;44(2):179-192.
184. Michalska K, Karpiuk I, Krol M, Tyski S. Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem 2013; 21:577-591.
185. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009; 53:3236-3239.
186. Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm 2014; 71:621-633.
187. Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and-resistant staphylococci and enterococci. J Antimicrob Chemother 2009; 63:713-715.
188. Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008; 52:4442-4447.